ClinicalTrials.gg
TerminatedNCT04816214GEOMETRY-EUpdated Mar 5, 2024Results posted

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

A Phase 3 interventional study of Capmatinib and Osimertinib in Carcinoma, Non-Small-Cell Lung, sponsored by Novartis Pharmaceuticals. Terminated at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Novartis decided to terminate the study based on a business consideration and not related with any safety concerns. Randomized part was not initiated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing capmatinib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 3 under way, none of them phase 3. capmatinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
16th of 21
6 · median 35
Started
2021
with 1 other
Phase 3
2 of 21
none open now
Registered
15th of 21
by date
Lead sponsor
16 of 21
Novartis Pharmaceuticals

Among the 21 studies testing capmatinib in Carcinoma, Non-Small-Cell Lung, this one is the 16th largest by enrollment, is one of 2 that started in 2021, is one of 2 in phase 3, and was the 15th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 21 studies testing capmatinib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About capmatinib

capmatinib: first FDA approval 2020 (TABRECTA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing capmatinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study aimed to evaluate the anticancer activity of capmatinib in combination with osimertinib compared to platinum-pemetrexed based doublet chemotherapy as second line treatment in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation, T790M negative, mesenchymal-to-epithelial transition factor (MET) amplified who progressed following EGFR tyrosine kinase inhibitors (TKIs).

Read the detailed description

This was a multicenter, open-label, randomized, active-controlled, global phase III study that enrolled adult participants with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) activating mutation, T790M negative, mesenchymal-to-epithelial transition factor (MET) amplified who had progressed following EGFR tyrosine kinase inhibitors (TKIs).

The study was conducted in two parts. The initial part was a safety run-in part, which aimed at assessing the safety and tolerability of capmatinib in combination with osimertinib and at determining the recommended dosage for the subsequent randomized part. The randomized part compared the efficacy and safety of capmatinib in combination with osimertinib to a platinum-based doublet chemotherapy regimen using either cisplatin or carboplatin, combined with pemetrexed, as second-line treatment.The randomized part was not initiated.

In the randomized part (if initiated), participants were to receive their assigned treatment (either capmatinib in combination with osimertinib or platinum-pemetrexed based doublet chemotherapy) until they experienced any of the following: documented disease progression according to the Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) as assessed by the investigator during the run-in part and confirmed by a blinded independent review committee (BIRC) during the randomized part, withdrawal of consent, pregnancy, lost to follow-up, or death. Participants who progressed in the platinum-pemetrexed arm were to be permitted to switch to capmatinib in combination with osimertinib therapy after BIRC-confirmed, RECIST 1.1-defined progressive disease. If, in the judgment of the investigator, there was evidence of clinical benefit and the participant wished to continue, study treatment could be continued beyond the initial disease progression according to RECIST 1.1 criteria. After treatment discontinuation, all participants were to be followed for safety evaluations during the safety follow-up period.

On 11-May-2022, Novartis decided to halt enrollment for this study due to a business consideration unrelated to any safety concerns. Ongoing patients in the run-in part were allowed to continue treatment through other post-trial drug supply options, as applicable. On 27-Dec-2022 the last patient was transitioned off the study, and following the study protocol this date was declared the Global end of trial date. Randomized part was not initiated.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • INC280
  • capmatinib
  • osimertinib
  • pemetrexed
  • platinum-based chemotherapy
  • NSCLC
  • Non-Small Cell Lung Cancer
  • Carcinoma
  • EGFR Mutation
  • T790M negative
  • MET amplification
  • second line therapy
  • GEOMETRY
  • GEOMETRY-E
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • or cytologically confirmed diagnosis of NSCLC with EGFR mutations known to be associated with EGFR TKI sensitivity, EGFR T790M negative and MET gene amplification
  • Stage IIIB/IIIC or IV NSCLC
  • Participants must have progressed on one (1st/2nd generation EGFR TKIs, osimertinib or other third generation EGFR TKIs) for advanced/ disease (stage IIIB/IIIC and must be candidates for platinum (cisplatin or carboplatin) - pemetrexed doublet based chemotherapy
  • (ECOG) performance status (PS) of 0 or 1
  • Participants must have recovered from all toxicities related to prior systemic therapy to grade ≤ 1 Common Terminology Criteria Adverse Event 5.0 ( v 5.0)
  • At least one as defined by 1.1
  • Participants must have adequate organ function

Key Exclusion Criteria:

  • Prior treatment with any MET inhibitor or HGF-targeting therapy
  • Participants with symptomatic central nervous system (CNS) metastases who were neurologically unstable or had required increasing doses of within the 2 weeks prior to study entry to manage CNS symptoms
  • Carcinomatous meningitis
  • Presence or history of a malignant disease other than NSCLC that had been diagnosed and/or required therapy within the past 3 years
  • Presence or history of interstitial lung disease or interstitial pneumonitis, including radiation pneumonitis
  • Long syndrome, family history of idiopathic sudden death or congenital long QT syndrome
  • Clinically significant, uncontrolled heart diseases
  • known druggable molecular alterations that may render participants eligible for alternative targeted therapies
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Run-in part: Capmatinib + Osimertinib

    In the run-in part, up to two dose levels of capmatinib in combination with osimertinib were planned to be investigated. The initial dose level for the combination therapy was capmatinib 400 mg orally twice daily (b.i.d) and osimertinib 80 mg orally once per day (q.d). If a dose de-escalation was necessary, a lower dose level was defined as capmatinib 400 mg orally b.i.d and osimertinib 40 mg orally q.d.

    Drug: Capmatinib · Drug: Osimertinib

  • Experimental
    Randomized part: Capmatinib + Osimertinib

    In the randomized part, capmatinib in combination with osimertinib was to be administered at the recommended Phase III regimen (defined in the safety run-in part). The study was terminated early based on Sponsor's decision unrelated to safety concerns and the randomized part of the study was not initiated.

    Drug: Capmatinib · Drug: Osimertinib

  • Active comparator
    Randomized Part: Platinum + Pemetrexed Based Doublet Chemotherapy

    In the randomized part, platinum-pemetrexed based doublet chemotherapy was to follow local guidelines as per standard of care and products labels. Participants randomized to platinum-pemetrexed based doublet chemotherapy arm were to be allowed to crossover to receive capmatinib in combination with osimertinib. The study was terminated early based on Sponsor's decision unrelated to safety concerns and the randomized part of the study was not initiated.

    Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin

Interventions

  • Capmatinib was available as a film-coated tablet for oral use, with a strength of either 150 mg or 200 mg. The initial dose of the combination therapy consisted of capmatinib 400 mg administered orally twice daily (b.i.d).

    Also known as: INC280

  • Osimertinib was available as a tablet for oral use, with a strength of either 80 mg or 40 mg. The initial dose of the combination therapy consisted of osimertinib 80 mg administered orally once per day (q.d)

  • Pemetrexed concentrate for solution for intravenous use was to be administered intravenously. The procurement of pemetrexed was to be done locally, following local practices and regulations.

  • Cisplatin concentrate for solution for intravenous use was to beadministered intravenously during the study. The procurement of cisplatin was to be done locally, following local practices and regulations.

  • Carboplatin concentrate for solution for intravenous use was to be administered intravenously during the study. The procurement of carboplatin was to be done locally, following local practices and regulations.

06

What researchers measure

Primary outcomes

  1. Run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs)

    A DLT was defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, progressive disease, inter-current illness, or concomitant medications, that despite optimal therapeutic intervention that occurred within the first 21 days of treatment with capmatinib in combination with osimertinib.

    Time frame: Up to 21 Days

  2. Randomized Part: Progression Free Survival (PFS) Based on BIRC Assessment

    PFS was defined as time from date of randomization to the date of first documented disease progression (PD) based on Blinded Independent Review Committee (BIRC) as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), or death from any cause, whichever occurred first. Progression was defined as a ≥20% increase in sum of longest diameters (SLD) compared to smallest SLD in the study, or progression of non-target lesions or new lesions.

    Time frame: From randomization to first documented progression or deaths, planned to be assessed up to 37 months

Secondary outcomes

  1. Run-in Part: Number of Participants With at Least One Dose Interruption and Dose Reduction of Each Study Drug

    Number of participants with at least one dose interruption and dose reduction were reported for each study drug.

    Time frame: From the first dose until last dose of study treatment, assessed up to 39 weeks

  2. Run-in Part: Dose Intensity of Each Study Drug

    Dose intensity was computed as the ratio of actual cumulative dose (milligrams) received and actual duration of exposure (weeks) to study drug.

    Time frame: From the first dose until last dose of study treatment, assessed up to 39 weeks

  3. Run-in Part: Median Duration of Exposure to Each Study Drug

    Duration of exposure is defined as the time (in weeks) between the first and the last dose of study treatment.

    Time frame: From the first dose until last dose of study treatment, assessed up to 39 weeks

  4. Run-in Part: Maximum Plasma Concentration (Cmax) of Capmatinib

    Blood samples were collected. Cmax of capmatinib was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics. Actual recorded sampling times were considered for the calculations

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Days 1 and 15 of Cycle 1 (Cycle = 21 days)

  5. Run-in Part: Maximum Plasma Concentration (Cmax) of Osimertinib and Its Metabolites (AZ5104 and AZ7550)

    Blood samples were collected. Cmax of osimertinib and its metabolites (AZ5104 and AZ7550) was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Days 1 and 15 of Cycle 1 (Cycle = 21 days)

  6. Run-in Part: Time to Maximum Plasma Concentration (Tmax) of Capmatinib

    Blood samples were collected. Tmax of capmatinib was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics. Actual recorded sampling times were considered for the calculations

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Days 1 and 15 of Cycle 1 (Cycle = 21 days)

  7. Run-in Part: Time to Maximum Plasma Concentration (Tmax) of Osimertinib and Its Metabolites (AZ5104 and AZ7550)

    Blood samples were collected. Tmax of osimertinib and its metabolites (AZ5104 and AZ7550) was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics. Actual recorded sampling times were considered for the calculations

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Days 1 and 15 of Cycle 1 (Cycle = 21 days)

  8. Run-in Part: Area Under the Curve to the Last Measurable Concentration (AUClast) of Capmatinib

    Blood samples were collected. AUClast of capmatinib was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Days 1 and 15 of Cycle 1 (Cycle = 21 days)

  9. Run-in Part: Area Under the Curve to the Last Measurable Concentration (AUClast) of Osimertinib and Its Metabolites (AZ5104 and AZ7550)

    Blood samples were collected. AUClast of osimertinib and its metabolites (AZ5104 and AZ7550) was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Days 1 and 15 of Cycle 1 (Cycle = 21 days)

  10. Run-in Part: Overall Response Rate (ORR) as Per Investigator Assessment

    ORR was defined as the percentage of participants with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR), as per investigator judgment and according to RECIST v1.1. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in the SLD of the target lesions or no new lesions or no progression of non-target lesions.

    Time frame: Up to end of study, assessed up to 39 weeks

  11. Run-in Part: Duration of Response (DOR) as Per Investigator Assessment

    DOR was defined as the time from first documented response of CR or PR to the date of first documented PD or death due to any cause. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in the SLD of the target lesions or no new lesions or no progression of non-target lesions; PD: ≥20% increase in SLD compared to the smallest SLD in the study, or progression of non-target lesions or new lesions.

    Time frame: Up to disease progression or death or end of study, assessed up to 39 weeks

  12. Run-in Part: Time to Response (TTR) as Per Investigator Assessment

    TTR was defined as the duration of time between the date of fist dose of treatmwnr and the date of the first documented response of either CR or PR as per investigator judgment and according to RECIST v1.1 criteria. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in SLD of the target lesions or no new lesions or no progression of non-target lesions.

    Time frame: From first dose of treatment up to end of study, assessed up to 39 weeks

  13. Run-in Part: Disease Control Rate (DCR) as Per Investigator Assessment

    DCR was defined as the percentage of participants with a BOR of CR, PR, and stable disease (SD) as per investigator judgment and according to RECIST v1.1. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in SLD of the target lesions or no new lesions or no progression of non-target lesions; SD: Neither sufficient shrinkage to qualify for PR or CR nor and increase in lesions which would qualify for PD. PD: ≥20% increase in SLD compared to the smallest SLD in the study, or progression of non-target lesions or new lesions.

    Time frame: From randomization up to end of study, assessed up to 39 weeks

  14. Run-in Part: Progression-Free Survival (PFS) as Per Investigator Assessment

    PFS was defined as the time (in months) from first dose of treatment to the date of the first documented progression or death due to any cause as per investigator judgment and according to RECIST v1.1. Progression was defined as a ≥20% increase in SLD compared to smallest SLD in the study, or progression of non-target lesions or new lesions. PFS was censored if no PFS event (progression or death) was observed.

    Time frame: From first dose of treatment until first documented progression or death or end of study, assessed up to 39 weeks

  15. Randomized Part: Overall Response Rate (ORR) as Per BIRC Assessment

    ORR was defined as the percentage of participants with confirmed BOR of CR or PR, as per BIRC by RECIST v1.1. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in SLD of the target lesions or no new lesions or no progression of non-target lesions.

    Time frame: Planned to be assessed up to 37 months

  16. Randomized Part: Overall Intracranial Response Rate (OIRR) as Per BIRC Assessment

    OIRR was defined as the percentage of participants with a confirmed best overall intracranial response (BOIR) of CR or PR as per BIRC according to Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria. Criteria for CR: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks, with no new lesions, and no use of corticosteroids. PR: ≥30% decrease in the SLD of CNS target lesions or no new lesions or and stable to decreased corticosteroid dose.

    Time frame: Planned to be assessed up to 37 months

  17. Randomized Part: Duration of Response (DOR) as Per BIRC Assessment

    DOR was defined as the time from the first documented response of CR or PR to the date of first documented progression or death as per BIRC according to RECIST v1.1 criteria. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in SLD of the target lesions or no new lesions or no progression of non-target lesions; PD: ≥20% increase in SLD compared to the smallest SLD in the study, or progression of non-target lesions or new lesions.

    Time frame: From first documented response to first documented progression or death, planned to be assessed up to 37 months

  18. Randomized Part: Time to Response (TTR) as Per BIRC Assessment

    TTR was defined as duration of time between the date of randomization and the date of first documented response of either CR or PR as per BIRC according to RECIST v1.1 criteria. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in SLD of the target lesions or no new lesions or no progression of non-target lesions.

    Time frame: From randomization to first documented response, planned to be assessed up to 37 months

  19. Randomized Part: Disease Control Rate (DCR) as Per BIRC Assessment

    DCR was defined as the percentage of participants with CR or PR or SD as per BIRC according to RECIST v1.1 criteria. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in SLD of the target lesions or no new lesions or no progression of non-target lesions; SD: Neither sufficient shrinkage to qualify for PR or CR nor and increase in lesions which would qualify for PD. PD: ≥20% increase in SLD compared to the smallest SLD in the study, or progression of non-target lesions or new lesions.

    Time frame: Planned to be assessed up to 37 months

  20. Randomized Part: Progression-Free Survival After Next Line of Treatment (PFS2) as Per Investigator Assessment

    PFS2 was defined as the time from date of randomization to the first documented progression on the next line therapy as per investigator judgment according to RECIST v1.1 response criteria or death due to any cause.

    Time frame: Planned to be assessed up to 37 months

  21. Randomized Part: Maximum Plasma Concentration (Cmax) of Capmatinib

    Cmax of capmatinib calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4 and 6 (Cycle = 21 days)

  22. Randomized Part: Maximum Plasma Concentration (Cmax) of Osimertinib and Its Metabolites

    Cmax of osimertinib and its metabolites (AZ5104 and AZ7550) calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

    Time frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4 and 6 (Cycle = 21 days)

  23. Randomized Part: Overall Survival (OS)

    OS was defined as the time from date of randomization to date of death due to any cause.

    Time frame: From randomization to date of death, planned to be assessed up to 37 months

  24. Randomized Part: Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (EORTC QLQ-C30) Score

    EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It contains 30 items and is composed of both multi-item scales and single-item measures based on the participant's experience over the past week. These include five scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, nausea/vomiting, and pain), six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact) and a global health status/quality of life scale (QoL) scale. All of the scales and single-item measures range in score from 0 to 100. A high score for a functional scale represents a high /healthy level of functioning; a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology/problems.

    Time frame: Cycle 1 Day 1, Cycle 3 Day 1, then every 6 weeks for the 18 months after Cycle 1 Day 1 and every 12 weeks thereafter, until end of treatment, end of treatment and 6, 12 and 18 weeks post-progression (Cycle = 21 days)

  25. Randomized Part: Change From Baseline in the EORTC QLQ Lung Cancer Module (EORTC QLQ-LC13) Score

    EORTC QLQ-LC13 is used in conjunction with the EORTC QLQ-C30 and provides information on an additional 13 items specifically related to lung cancer. The five domains of the LC13 include pain, dyspnea, coughing and hemoptysis, and are based on their presence over the past week. All but the pain domain are scored on a 4 point Likert scale ranging from "not at all" to "very much". Pain score is based on its presence, hence yes or no. Scores are averaged and transformed to 0 to 100. A higher score indicates a higher presence of symptoms.

    Time frame: Cycle 1 Day 1, Cycle 3 Day 1, then every 6 weeks for the 18 months after Cycle 1 Day 1 and every 12 weeks thereafter, until end of treatment, end of treatment and 6, 12 and 18 weeks post-progression (Cycle = 21 days)

  26. Randomized Part: Change From Baseline in the EuroQoL-5 Dimension-5 Level (EQ-5D-5L) Score

    EQ-5D-5L is a standardized measure of health status developed by the EuroQol (EQ) Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 pages - the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of these dimensions, the participant self-assigned a score: from 1 (no problems) to 5 (extreme problems). The questionnaire also includes a Visual Analogue Scale (VAS), where the participant is asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state.

    Time frame: Cycle 1 Day 1, Cycle 3 Day 1, then every 6 weeks for the 18 months after Cycle 1 Day 1 and every 12 weeks thereafter, until end of treatment, end of treatment and 6, 12 and 18 weeks post-progression (Cycle = 21 days)

  27. Randomized Part: Change From Baseline in the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN FACT)-Brain Symptom Index Version 2.0 (FBrSI)

    The NCCN FACT-Brain Symptom Index version 2.0 (FBrSI) is a questionnaire used to explore changes in symptoms associated with potential brain metastases (BM). The symptoms module contains 12 items with a recall period of the past 7 days. The participant responds to 12 statements and indicates to what extent it applies to them on a 5-point Likert response scale from "not at all"=0 to "very much"=4. Higher scores indicates a greater impact of symptoms on the participant's quality of life.

    Time frame: Cycle 1 Day 1, Cycle 3 Day 1, then every 6 weeks for the 18 months after Cycle 1 Day 1 and every 12 weeks thereafter, until end of treatment, end of treatment and 6, 12 and 18 weeks post-progression (Cycle = 21 days)

  28. Randomized Part: Time to Symptom Deterioration for EORTC QLQ-C30 Questionnaire

    Time to symptom deterioration from baseline from baseline for participant scores from the EORTC QLQ-C30 questionnaire. EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It contains 30 items and is composed of both multi-item scales and single-item measures based on the participant's experience over the past week. These include five scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, nausea/vomiting, and pain), six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact) and a global health status/quality of life scale (QoL) scale. All of the scales and single-item measures range in score from 0 to 100. A high score for a functional scale represents a high /healthy level of functioning; a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology/problems.

    Time frame: From baseline to symptom deterioration, planned to be assessed up to 37 months

  29. Randomized Part: Time to Symptom Deterioration for EORTC QLQ-LC13 Questionnaire

    Time to symptom deterioration from baseline for participant scores from EORTC QLQ-LC13 questionnaire. EORTC QLQ-LC13 is used in conjunction with the EORTC QLQ-C30 and provides information on an additional 13 items specifically related to lung cancer. The five domains of the LC13 include pain, dyspnea, coughing and hemoptysis, and are based on their presence over the past week. All but the pain domain are scored on a 4 point Likert scale ranging from "not at all" to "very much". Pain score is based on its presence, hence yes or no. Scores are averaged and transformed to 0 to 100. A higher score indicates a higher presence of symptoms.

    Time frame: From baseline to symptom deterioration, planned to be assessed up to 37 months

  30. Randomized Part: Time to Symptom Deterioration for NCCN FBrSl Questionnaire

    Time to symptom deterioration from baseline for participant scores from the NCCN FBrSl questionnaire. The NCCN FACT-Brain Symptom Index version 2.0 (FBrSI) is a questionnaire used to explore changes in symptoms associated with potential brain metastases (BM). The symptoms module contains 12 items with a recall period of the past 7 days. The participant responds to 12 statements and indicates to what extent it applies to them on a 5-point Likert response scale from "not at all"=0 to "very much"=4. Higher scores indicates a greater impact of symptoms on the participant's quality of life.

    Time frame: From baseline to symptom deterioration, planned to be assessed up to 37 months

  31. Randomized Part: Duration of Intracranial Response (DOIR) Based on BIRC

    DOIR was defined as the time from the date of first documented intracranial response of either CR or PR to the date of the first documented intracranial progression per RANO-BM criteria as assessed by BIRC review or the date of death due to any cause. Criteria for CR: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks, with no new lesions, and no use of corticosteroids; PR: ≥30% decrease in the SLD of CNS target lesions or no new lesions, and stable to decreased corticosteroid dose.

    Time frame: From the date of first documented intracranial response to first documented intracranial progression or death, planned to be assessed up to 37 months

  32. Randomized Part: Time to Intracranial Response (TTIR) Based on BIRC

    TTIR was defined as the time from the date of randomization to the date of the first documented intracranial response of either CR or PR as per BIRC according to RANO-BM criteria. Criteria for CR: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks, with no new lesions, and no use of corticosteroids; PR: ≥30% decrease in the SLD of CNS target lesions or no new lesions, and stable to decreased corticosteroid dose.

    Time frame: From randomization to first documented response, planned to be assessed up to 37 months

  33. Randomized Part: Intracranial Disease Control Rate (IDCR) Based on BIRC

    IDCR was defined as the percentage of participants with a confirmed BOIR of CR or PR or SD as per BIRC according to RANO-BM criteria. Criteria for CR: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks, with no new lesions, and no use of corticosteroids; PR: ≥30% decrease in the SLD of CNS target lesions or no new lesions, and stable to decreased corticosteroid dose; SD: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

    Time frame: Planned to be assessed up to 37 months

07

Results

Posted Oct 30, 2023

Participant flow

In the run-in part, participants were enrolled at 4 investigative sites in 3 countries. The study was terminated early based on Sponsor's decision unrelated to any safety concerns and the randomized part of the study was not initiated.

Participant flow — Overall Study
MilestoneRun-in Part: Capmatinib + OsimertinibRandomized Part: Capmatinib + OsimertinibRandomized Part: Platinum + Pemetrexed Based Doublet Chemotherapy
Started600
Full analysis set (fas)600
Safety set600
Pharmacokinetic (pk) analysis set600
Completed000
Not completed600
Withdrew: Progressive disease400
Withdrew: Death100
Withdrew: Study terminated by sponsor100

Outcome measures

PrimaryRun-in Part: Number of Participants With Dose Limiting Toxicities (DLTs)

A DLT was defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, progressive disease, inter-current illness, or concomitant medications, that despite optimal therapeutic intervention that occurred within the first 21 days of treatment with capmatinib in combination with osimertinib.

Time frame:
Up to 21 Days
Reported as:
Count of participants · Participants
Run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsRun-in Part: Capmatinib + Osimertinib
Run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs)0
PrimaryRandomized Part: Progression Free Survival (PFS) Based on BIRC Assessment

PFS was defined as time from date of randomization to the date of first documented disease progression (PD) based on Blinded Independent Review Committee (BIRC) as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), or death from any cause, whichever occurred first. Progression was defined as a ≥20% increase in sum of longest diameters (SLD) compared to smallest SLD in the study, or progression of non-target lesions or new lesions.

Time frame:
From randomization to first documented progression or deaths, planned to be assessed up to 37 months

No measurements were reported for this outcome.

SecondaryRun-in Part: Number of Participants With at Least One Dose Interruption and Dose Reduction of Each Study Drug

Number of participants with at least one dose interruption and dose reduction were reported for each study drug.

Time frame:
From the first dose until last dose of study treatment, assessed up to 39 weeks
Reported as:
Count of participants · Participants
Run-in Part: Number of Participants With at Least One Dose Interruption and Dose Reduction of Each Study Drug
ParticipantsRun-in Part: Capmatinib + Osimertinib
Dose Interruption: Capmatinib5
Dose Interruption: Osimertinib4
Dose Reduction: Capmatinib3
Dose Reduction: Osimertinib0
SecondaryRun-in Part: Dose Intensity of Each Study Drug

Dose intensity was computed as the ratio of actual cumulative dose (milligrams) received and actual duration of exposure (weeks) to study drug.

Time frame:
From the first dose until last dose of study treatment, assessed up to 39 weeks
Reported as:
Mean · milligrams per week (mg/week)
Run-in Part: Dose Intensity of Each Study Drug
milligrams per week (mg/week)Run-in Part: Capmatinib + Osimertinib
Capmatinib5042.8 ± 947.28
Osimertinib534.9 ± 41.29
SecondaryRun-in Part: Median Duration of Exposure to Each Study Drug

Duration of exposure is defined as the time (in weeks) between the first and the last dose of study treatment.

Time frame:
From the first dose until last dose of study treatment, assessed up to 39 weeks
Reported as:
Median · weeks
Run-in Part: Median Duration of Exposure to Each Study Drug
weeksRun-in Part: Capmatinib + Osimertinib
Capmatinib23.5 (1 to 39)
Osimertinib24.0 (1 to 39)
SecondaryRun-in Part: Maximum Plasma Concentration (Cmax) of Capmatinib

Blood samples were collected. Cmax of capmatinib was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics. Actual recorded sampling times were considered for the calculations

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Days 1 and 15 of Cycle 1 (Cycle = 21 days)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Run-in Part: Maximum Plasma Concentration (Cmax) of Capmatinib
nanograms per milliliter (ng/mL)Run-in Part: Capmatinib + Osimertinib
Day 15510 ± 2380
Day 155750 ± 1050
SecondaryRun-in Part: Maximum Plasma Concentration (Cmax) of Osimertinib and Its Metabolites (AZ5104 and AZ7550)

Blood samples were collected. Cmax of osimertinib and its metabolites (AZ5104 and AZ7550) was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Days 1 and 15 of Cycle 1 (Cycle = 21 days)
Reported as:
Mean · ng/mL
Run-in Part: Maximum Plasma Concentration (Cmax) of Osimertinib and Its Metabolites (AZ5104 and AZ7550)
ng/mLRun-in Part: Capmatinib + Osimertinib
Osimertinib: Day 199.5 ± 57.0
Osimertinib: Day 15265 ± 113
AZ5104: Day 14.86 ± 3.22
AZ5104: Day 1522.0 ± 9.23
AZ7550: Day 13.61 ± 1.53
AZ7550: Day 1533.0 ± 11.9
SecondaryRun-in Part: Time to Maximum Plasma Concentration (Tmax) of Capmatinib

Blood samples were collected. Tmax of capmatinib was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics. Actual recorded sampling times were considered for the calculations

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Days 1 and 15 of Cycle 1 (Cycle = 21 days)
Reported as:
Median · hours
Run-in Part: Time to Maximum Plasma Concentration (Tmax) of Capmatinib
hoursRun-in Part: Capmatinib + Osimertinib
Day 11.92 (0.983 to 3.02)
Day 151.00 (0.917 to 1.82)
SecondaryRun-in Part: Time to Maximum Plasma Concentration (Tmax) of Osimertinib and Its Metabolites (AZ5104 and AZ7550)

Blood samples were collected. Tmax of osimertinib and its metabolites (AZ5104 and AZ7550) was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics. Actual recorded sampling times were considered for the calculations

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Days 1 and 15 of Cycle 1 (Cycle = 21 days)
Reported as:
Median · hours
Run-in Part: Time to Maximum Plasma Concentration (Tmax) of Osimertinib and Its Metabolites (AZ5104 and AZ7550)
hoursRun-in Part: Capmatinib + Osimertinib
Osimertinib: Day 16.00 (2.90 to 23.1)
Osimertinib: Day 154.00 (0.00 to 7.33)
AZ5104: Day 123.1 (22.3 to 23.5)
AZ5104: Day 154.00 (0.00 to 7.13)
AZ7550: Day 15.68 (2.90 to 23.1)
AZ7550: Day 152.25 (0.00 to 6.00)
SecondaryRun-in Part: Area Under the Curve to the Last Measurable Concentration (AUClast) of Capmatinib

Blood samples were collected. AUClast of capmatinib was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose on Days 1 and 15 of Cycle 1 (Cycle = 21 days)
Reported as:
Mean · nanograms*hours/milliliter (ng*hr/mL)
Run-in Part: Area Under the Curve to the Last Measurable Concentration (AUClast) of Capmatinib
nanograms*hours/milliliter (ng*hr/mL)Run-in Part: Capmatinib + Osimertinib
Day 120100 ± 6080
Day 1521300 ± 7050
SecondaryRun-in Part: Area Under the Curve to the Last Measurable Concentration (AUClast) of Osimertinib and Its Metabolites (AZ5104 and AZ7550)

Blood samples were collected. AUClast of osimertinib and its metabolites (AZ5104 and AZ7550) was calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose on Days 1 and 15 of Cycle 1 (Cycle = 21 days)
Reported as:
Mean · ng*hr/mL
Run-in Part: Area Under the Curve to the Last Measurable Concentration (AUClast) of Osimertinib and Its Metabolites (AZ5104 and AZ7550)
ng*hr/mLRun-in Part: Capmatinib + Osimertinib
Osimertinib: Day 11790 ± 1030
Osimertinib: Day 151380 ± 900
AZ5104: Day 182.9 ± 59.4
AZ5104: Day 15136 ± 56.8
AZ7550: Day 147.1 ± 46.3
AZ7550: Day 15112 ± 111
SecondaryRun-in Part: Overall Response Rate (ORR) as Per Investigator Assessment

ORR was defined as the percentage of participants with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR), as per investigator judgment and according to RECIST v1.1. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in the SLD of the target lesions or no new lesions or no progression of non-target lesions.

Time frame:
Up to end of study, assessed up to 39 weeks
Reported as:
Number · percentage of participants
Run-in Part: Overall Response Rate (ORR) as Per Investigator Assessment
percentage of participantsRun-in Part: Capmatinib + Osimertinib
Run-in Part: Overall Response Rate (ORR) as Per Investigator Assessment50.0 (11.8 to 88.2)
SecondaryRun-in Part: Duration of Response (DOR) as Per Investigator Assessment

DOR was defined as the time from first documented response of CR or PR to the date of first documented PD or death due to any cause. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in the SLD of the target lesions or no new lesions or no progression of non-target lesions; PD: ≥20% increase in SLD compared to the smallest SLD in the study, or progression of non-target lesions or new lesions.

Time frame:
Up to disease progression or death or end of study, assessed up to 39 weeks
Reported as:
Median · months
Run-in Part: Duration of Response (DOR) as Per Investigator Assessment
monthsRun-in Part: Capmatinib + Osimertinib
Run-in Part: Duration of Response (DOR) as Per Investigator Assessment6.93 (2.50 to NA)
SecondaryRun-in Part: Time to Response (TTR) as Per Investigator Assessment

TTR was defined as the duration of time between the date of fist dose of treatmwnr and the date of the first documented response of either CR or PR as per investigator judgment and according to RECIST v1.1 criteria. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in SLD of the target lesions or no new lesions or no progression of non-target lesions.

Time frame:
From first dose of treatment up to end of study, assessed up to 39 weeks
Reported as:
Median · months
Run-in Part: Time to Response (TTR) as Per Investigator Assessment
monthsRun-in Part: Capmatinib + Osimertinib
Run-in Part: Time to Response (TTR) as Per Investigator AssessmentNA (1.41 to NA)
SecondaryRun-in Part: Disease Control Rate (DCR) as Per Investigator Assessment

DCR was defined as the percentage of participants with a BOR of CR, PR, and stable disease (SD) as per investigator judgment and according to RECIST v1.1. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in SLD of the target lesions or no new lesions or no progression of non-target lesions; SD: Neither sufficient shrinkage to qualify for PR or CR nor and increase in lesions which would qualify for PD. PD: ≥20% increase in SLD compared to the smallest SLD in the study, or progression of non-target lesions or new lesions.

Time frame:
From randomization up to end of study, assessed up to 39 weeks
Reported as:
Number · percentage of participants
Run-in Part: Disease Control Rate (DCR) as Per Investigator Assessment
percentage of participantsRun-in Part: Capmatinib + Osimertinib
Run-in Part: Disease Control Rate (DCR) as Per Investigator Assessment66.7 (22.3 to 95.7)
SecondaryRun-in Part: Progression-Free Survival (PFS) as Per Investigator Assessment

PFS was defined as the time (in months) from first dose of treatment to the date of the first documented progression or death due to any cause as per investigator judgment and according to RECIST v1.1. Progression was defined as a ≥20% increase in SLD compared to smallest SLD in the study, or progression of non-target lesions or new lesions. PFS was censored if no PFS event (progression or death) was observed.

Time frame:
From first dose of treatment until first documented progression or death or end of study, assessed up to 39 weeks
Reported as:
Median · months
Run-in Part: Progression-Free Survival (PFS) as Per Investigator Assessment
monthsRun-in Part: Capmatinib + Osimertinib
Run-in Part: Progression-Free Survival (PFS) as Per Investigator Assessment4.58 (0.99 to NA)
SecondaryRandomized Part: Overall Response Rate (ORR) as Per BIRC Assessment

ORR was defined as the percentage of participants with confirmed BOR of CR or PR, as per BIRC by RECIST v1.1. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in SLD of the target lesions or no new lesions or no progression of non-target lesions.

Time frame:
Planned to be assessed up to 37 months

No measurements were reported for this outcome.

SecondaryRandomized Part: Overall Intracranial Response Rate (OIRR) as Per BIRC Assessment

OIRR was defined as the percentage of participants with a confirmed best overall intracranial response (BOIR) of CR or PR as per BIRC according to Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria. Criteria for CR: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks, with no new lesions, and no use of corticosteroids. PR: ≥30% decrease in the SLD of CNS target lesions or no new lesions or and stable to decreased corticosteroid dose.

Time frame:
Planned to be assessed up to 37 months

No measurements were reported for this outcome.

SecondaryRandomized Part: Duration of Response (DOR) as Per BIRC Assessment

DOR was defined as the time from the first documented response of CR or PR to the date of first documented progression or death as per BIRC according to RECIST v1.1 criteria. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in SLD of the target lesions or no new lesions or no progression of non-target lesions; PD: ≥20% increase in SLD compared to the smallest SLD in the study, or progression of non-target lesions or new lesions.

Time frame:
From first documented response to first documented progression or death, planned to be assessed up to 37 months

No measurements were reported for this outcome.

SecondaryRandomized Part: Time to Response (TTR) as Per BIRC Assessment

TTR was defined as duration of time between the date of randomization and the date of first documented response of either CR or PR as per BIRC according to RECIST v1.1 criteria. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in SLD of the target lesions or no new lesions or no progression of non-target lesions.

Time frame:
From randomization to first documented response, planned to be assessed up to 37 months

No measurements were reported for this outcome.

SecondaryRandomized Part: Disease Control Rate (DCR) as Per BIRC Assessment

DCR was defined as the percentage of participants with CR or PR or SD as per BIRC according to RECIST v1.1 criteria. Criteria for CR: Disappearance of all lesions and pathologic lymph nodes; PR: ≥30% decrease in SLD of the target lesions or no new lesions or no progression of non-target lesions; SD: Neither sufficient shrinkage to qualify for PR or CR nor and increase in lesions which would qualify for PD. PD: ≥20% increase in SLD compared to the smallest SLD in the study, or progression of non-target lesions or new lesions.

Time frame:
Planned to be assessed up to 37 months

No measurements were reported for this outcome.

SecondaryRandomized Part: Progression-Free Survival After Next Line of Treatment (PFS2) as Per Investigator Assessment

PFS2 was defined as the time from date of randomization to the first documented progression on the next line therapy as per investigator judgment according to RECIST v1.1 response criteria or death due to any cause.

Time frame:
Planned to be assessed up to 37 months

No measurements were reported for this outcome.

SecondaryRandomized Part: Maximum Plasma Concentration (Cmax) of Capmatinib

Cmax of capmatinib calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Pre-dose on Day 1 of Cycles 1, 2, 3, 4 and 6 (Cycle = 21 days)

No measurements were reported for this outcome.

SecondaryRandomized Part: Maximum Plasma Concentration (Cmax) of Osimertinib and Its Metabolites

Cmax of osimertinib and its metabolites (AZ5104 and AZ7550) calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Time frame:
Pre-dose on Day 1 of Cycles 1, 2, 3, 4 and 6 (Cycle = 21 days)

No measurements were reported for this outcome.

SecondaryRandomized Part: Overall Survival (OS)

OS was defined as the time from date of randomization to date of death due to any cause.

Time frame:
From randomization to date of death, planned to be assessed up to 37 months

No measurements were reported for this outcome.

SecondaryRandomized Part: Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (EORTC QLQ-C30) Score

EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It contains 30 items and is composed of both multi-item scales and single-item measures based on the participant's experience over the past week. These include five scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, nausea/vomiting, and pain), six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact) and a global health status/quality of life scale (QoL) scale. All of the scales and single-item measures range in score from 0 to 100. A high score for a functional scale represents a high /healthy level of functioning; a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology/problems.

Time frame:
Cycle 1 Day 1, Cycle 3 Day 1, then every 6 weeks for the 18 months after Cycle 1 Day 1 and every 12 weeks thereafter, until end of treatment, end of treatment and 6, 12 and 18 weeks post-progression (Cycle = 21 days)

No measurements were reported for this outcome.

SecondaryRandomized Part: Change From Baseline in the EORTC QLQ Lung Cancer Module (EORTC QLQ-LC13) Score

EORTC QLQ-LC13 is used in conjunction with the EORTC QLQ-C30 and provides information on an additional 13 items specifically related to lung cancer. The five domains of the LC13 include pain, dyspnea, coughing and hemoptysis, and are based on their presence over the past week. All but the pain domain are scored on a 4 point Likert scale ranging from "not at all" to "very much". Pain score is based on its presence, hence yes or no. Scores are averaged and transformed to 0 to 100. A higher score indicates a higher presence of symptoms.

Time frame:
Cycle 1 Day 1, Cycle 3 Day 1, then every 6 weeks for the 18 months after Cycle 1 Day 1 and every 12 weeks thereafter, until end of treatment, end of treatment and 6, 12 and 18 weeks post-progression (Cycle = 21 days)

No measurements were reported for this outcome.

SecondaryRandomized Part: Change From Baseline in the EuroQoL-5 Dimension-5 Level (EQ-5D-5L) Score

EQ-5D-5L is a standardized measure of health status developed by the EuroQol (EQ) Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 pages - the descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each of these dimensions, the participant self-assigned a score: from 1 (no problems) to 5 (extreme problems). The questionnaire also includes a Visual Analogue Scale (VAS), where the participant is asked to rate current health status on a scale of 0 to 100, with 0 being the worst imaginable health state.

Time frame:
Cycle 1 Day 1, Cycle 3 Day 1, then every 6 weeks for the 18 months after Cycle 1 Day 1 and every 12 weeks thereafter, until end of treatment, end of treatment and 6, 12 and 18 weeks post-progression (Cycle = 21 days)

No measurements were reported for this outcome.

SecondaryRandomized Part: Change From Baseline in the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN FACT)-Brain Symptom Index Version 2.0 (FBrSI)

The NCCN FACT-Brain Symptom Index version 2.0 (FBrSI) is a questionnaire used to explore changes in symptoms associated with potential brain metastases (BM). The symptoms module contains 12 items with a recall period of the past 7 days. The participant responds to 12 statements and indicates to what extent it applies to them on a 5-point Likert response scale from "not at all"=0 to "very much"=4. Higher scores indicates a greater impact of symptoms on the participant's quality of life.

Time frame:
Cycle 1 Day 1, Cycle 3 Day 1, then every 6 weeks for the 18 months after Cycle 1 Day 1 and every 12 weeks thereafter, until end of treatment, end of treatment and 6, 12 and 18 weeks post-progression (Cycle = 21 days)

No measurements were reported for this outcome.

SecondaryRandomized Part: Time to Symptom Deterioration for EORTC QLQ-C30 Questionnaire

Time to symptom deterioration from baseline from baseline for participant scores from the EORTC QLQ-C30 questionnaire. EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It contains 30 items and is composed of both multi-item scales and single-item measures based on the participant's experience over the past week. These include five scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, nausea/vomiting, and pain), six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact) and a global health status/quality of life scale (QoL) scale. All of the scales and single-item measures range in score from 0 to 100. A high score for a functional scale represents a high /healthy level of functioning; a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology/problems.

Time frame:
From baseline to symptom deterioration, planned to be assessed up to 37 months

No measurements were reported for this outcome.

SecondaryRandomized Part: Time to Symptom Deterioration for EORTC QLQ-LC13 Questionnaire

Time to symptom deterioration from baseline for participant scores from EORTC QLQ-LC13 questionnaire. EORTC QLQ-LC13 is used in conjunction with the EORTC QLQ-C30 and provides information on an additional 13 items specifically related to lung cancer. The five domains of the LC13 include pain, dyspnea, coughing and hemoptysis, and are based on their presence over the past week. All but the pain domain are scored on a 4 point Likert scale ranging from "not at all" to "very much". Pain score is based on its presence, hence yes or no. Scores are averaged and transformed to 0 to 100. A higher score indicates a higher presence of symptoms.

Time frame:
From baseline to symptom deterioration, planned to be assessed up to 37 months

No measurements were reported for this outcome.

SecondaryRandomized Part: Time to Symptom Deterioration for NCCN FBrSl Questionnaire

Time to symptom deterioration from baseline for participant scores from the NCCN FBrSl questionnaire. The NCCN FACT-Brain Symptom Index version 2.0 (FBrSI) is a questionnaire used to explore changes in symptoms associated with potential brain metastases (BM). The symptoms module contains 12 items with a recall period of the past 7 days. The participant responds to 12 statements and indicates to what extent it applies to them on a 5-point Likert response scale from "not at all"=0 to "very much"=4. Higher scores indicates a greater impact of symptoms on the participant's quality of life.

Time frame:
From baseline to symptom deterioration, planned to be assessed up to 37 months

No measurements were reported for this outcome.

SecondaryRandomized Part: Duration of Intracranial Response (DOIR) Based on BIRC

DOIR was defined as the time from the date of first documented intracranial response of either CR or PR to the date of the first documented intracranial progression per RANO-BM criteria as assessed by BIRC review or the date of death due to any cause. Criteria for CR: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks, with no new lesions, and no use of corticosteroids; PR: ≥30% decrease in the SLD of CNS target lesions or no new lesions, and stable to decreased corticosteroid dose.

Time frame:
From the date of first documented intracranial response to first documented intracranial progression or death, planned to be assessed up to 37 months

No measurements were reported for this outcome.

SecondaryRandomized Part: Time to Intracranial Response (TTIR) Based on BIRC

TTIR was defined as the time from the date of randomization to the date of the first documented intracranial response of either CR or PR as per BIRC according to RANO-BM criteria. Criteria for CR: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks, with no new lesions, and no use of corticosteroids; PR: ≥30% decrease in the SLD of CNS target lesions or no new lesions, and stable to decreased corticosteroid dose.

Time frame:
From randomization to first documented response, planned to be assessed up to 37 months

No measurements were reported for this outcome.

SecondaryRandomized Part: Intracranial Disease Control Rate (IDCR) Based on BIRC

IDCR was defined as the percentage of participants with a confirmed BOIR of CR or PR or SD as per BIRC according to RANO-BM criteria. Criteria for CR: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks, with no new lesions, and no use of corticosteroids; PR: ≥30% decrease in the SLD of CNS target lesions or no new lesions, and stable to decreased corticosteroid dose; SD: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease.

Time frame:
Planned to be assessed up to 37 months

No measurements were reported for this outcome.

Adverse events

Collected over From first dose of treatment until 30 days after last dose of study treatment, assessed up to 39 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-in Part: Capmatinib + Osimertinib1/6 (16.7%)2/6 (33.3%)5/6 (83.3%)
Most frequent serious events
Most frequent serious events
EventRun-in Part: Capmatinib + Osimertinib
Pericardial effusionCardiac disorders1/6
NauseaGastrointestinal disorders1/6
COVID-19Infections and infestations1/6
PneumoniaInfections and infestations1/6
Decreased appetiteMetabolism and nutrition disorders1/6
Most frequent other events
Showing 10 of 25
Most frequent other events
EventRun-in Part: Capmatinib + Osimertinib
Oedema peripheralGeneral disorders4/6
HypoalbuminaemiaMetabolism and nutrition disorders3/6
RashSkin and subcutaneous tissue disorders3/6
NauseaGastrointestinal disorders2/6
NeutropeniaBlood and lymphatic system disorders1/6
Pericardial effusionCardiac disorders1/6
Ear discomfortEar and labyrinth disorders1/6
CataractEye disorders1/6
DiarrhoeaGastrointestinal disorders1/6
VomitingGastrointestinal disorders1/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Run-in Part: Capmatinib + Osimertinib
Mean61.7 ± 7.76
Sex: Female, Male
Sex: Female, Male(Participants)Run-in Part: Capmatinib + Osimertinib
Female4
Male2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Run-in Part: Capmatinib + Osimertinib
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

4 sites
  • Novartis Investigative Site
    Kashiwa, Chiba 277 8577, Japan
  • Novartis Investigative Site
    Sunto Gun, Shizuoka 411 8777, Japan
  • Novartis Investigative Site
    Seoul, 05505, Korea, Republic of
  • Novartis Investigative Site
    Singapore, 168583, Singapore
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Dec 2022, 15 months.

Results were first posted in Oct 2023, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2021
First posted
Mar 25, 2021
StartActual
Sep 22, 2021
Primary completionActual
Dec 27, 2022
CompletionActual
Dec 27, 2022
Results first posted
Oct 30, 2023
Last update
Mar 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04816214
Responsible party
Sponsor
First posted
Mar 25, 2021
Start date
Sep 22, 2021
Primary completion
Dec 27, 2022
Completion
Dec 27, 2022
Results posted
Oct 30, 2023
Last update
Mar 5, 2024

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capmatinib · Osimertinib

Start the discussion